Valuation: BioNTech SE

Market Cap 19.88B 22.91B 18.61B 17.03B 32.15B 2,182B 32.57B 218B 85.46B 1,090B 86.01B 84.14B 3,629B P/E 2026 *
-14.5x
P/E 2027 * -14.9x
Enterprise Value 9.1B 10.49B 8.52B 7.79B 14.71B 999B 14.91B 99.69B 39.12B 499B 39.37B 38.52B 1,661B EV / Sales 2026 *
4.97x
EV / Sales 2027 * 5.6x
Free-Float
96.06%
Yield 2026 *
-
Yield 2027 * -
1 day-1.07%
1 week-1.79%
Current month+0.67%
1 month-2.92%
3 months-4.27%
6 months-14.47%
Current year-4.21%
1 week 88.2
Extreme 88.2
94.41
1 month 88.2
Extreme 88.2
94.62
Current year 79.52
Extreme 79.52
124
1 year 79.52
Extreme 79.52
124
3 years 76.53
Extreme 76.5301
131.49
5 years 76.53
Extreme 76.5301
464
10 years 12.52
Extreme 12.525
464
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 59 01/01/2018
Chief Executive Officer 60 02/06/2008
Director of Finance/CFO - 01/07/2025
Director TitleAgeSince
Chairman 55 02/06/2008
Director/Board Member 69 02/06/2008
Director/Board Member 65 01/01/2018
Date Insider Type Main position Quantity % Market Cap.
18/3/26 Other

Director

1,927 0.0008%
Change 5-day change 1-year change 3-year change Capi.($)
-1.07%-1.79%-18.07%-14.36% 22.91B
-3.25%+13.72%+52.49%+88.86% 62.92B
+2.36%+3.57%+34.00%+74.53% 54.32B
+33.86%+30.60%+19.14%+502.77% 28.73B
+10.83%+18.38%+52.76%+4.58% 21.65B
+8.76%+9.87%+41.17%-19.64% 17.76B
-3.37%+25.85%+213.21%+369.13% 16.47B
+6.20%+11.51%+34.94%+681.88% 15.48B
-7.94%-6.74%+38.42%+157.52% 13.12B
-1.24%-1.71%+426.24%+171.18% 12.12B
Average +4.51%+7.10%+89.43%+201.65% 26.55B
Weighted average by Cap. +4.46%+8.14%+63.60%+166.80%

Financials

2026 *2027 *
Net sales 1.83B 2.11B 1.71B 1.57B 2.96B 201B 3B 20.05B 7.87B 100B 7.92B 7.75B 334B 1.86B 2.15B 1.75B 1.6B 3.01B 205B 3.05B 20.42B 8.01B 102B 8.07B 7.89B 340B
Net income -1.34B -1.54B -1.26B -1.15B -2.17B -147B -2.2B -14.69B -5.76B -73.53B -5.8B -5.67B -245B -1.35B -1.56B -1.27B -1.16B -2.19B -148B -2.22B -14.81B -5.81B -74.16B -5.85B -5.72B -247B
Net Debt -10.78B -12.42B -10.09B -9.23B -17.43B -1,183B -17.66B -118B -46.34B -591B -46.64B -45.62B -1,968B -9.44B -10.88B -8.84B -8.09B -15.27B -1,036B -15.47B -103B -40.59B -518B -40.85B -39.96B -1,724B
Logo BioNTech SE
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Employees
7,807
Date Price Change Volume
06/08/26 USD 91.19 -1.07% 1,349,965
05/08/26 USD 92.18 +0.91% 1,700,690
04/08/26 USD 91.35 -0.98% 2,000,003
03/08/26 USD 92.25 +1.84% 1,119,580
31/07/26 USD 90.58 -2.44% 710,906
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
79.13EUR
Average target price
104.27EUR
Spread / Average Target
+31.76%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BNTX Stock